Last reviewed · How we verify
AE37 Peptide vaccine
AE37 Peptide vaccine is a Biologic drug developed by NuGenerex Immuno-Oncology. It is currently in Phase 2 development for Metastatic breast cancer. Also known as: AE37.
AE37 Peptide vaccine stimulates the immune system to recognize and attack cancer cells.
AE37 Peptide vaccine stimulates the immune system to recognize and attack cancer cells. Used for Metastatic breast cancer.
At a glance
| Generic name | AE37 Peptide vaccine |
|---|---|
| Also known as | AE37 |
| Sponsor | NuGenerex Immuno-Oncology |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The AE37 Peptide vaccine is a type of cancer vaccine that works by presenting specific peptides from cancer cells to the immune system, allowing it to recognize and target these cells for destruction. This process is thought to induce a specific immune response against cancer cells, potentially leading to tumor shrinkage or slowing of disease progression.
Approved indications
- Metastatic breast cancer
Common side effects
- Injection site reaction
- Fatigue
- Pain
Key clinical trials
- Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (PHASE2)
- Vaccine Therapy in Treating Patients With Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AE37 Peptide vaccine CI brief — competitive landscape report
- AE37 Peptide vaccine updates RSS · CI watch RSS
- NuGenerex Immuno-Oncology portfolio CI
Frequently asked questions about AE37 Peptide vaccine
What is AE37 Peptide vaccine?
How does AE37 Peptide vaccine work?
What is AE37 Peptide vaccine used for?
Who makes AE37 Peptide vaccine?
Is AE37 Peptide vaccine also known as anything else?
What development phase is AE37 Peptide vaccine in?
What are the side effects of AE37 Peptide vaccine?
Related
- Manufacturer: NuGenerex Immuno-Oncology — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Also known as: AE37
- Compare: AE37 Peptide vaccine vs similar drugs
- Pricing: AE37 Peptide vaccine cost, discount & access